TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval

Ritu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day in a year.